|
|
Vaccine Detail
|
B16 melanoma DNA vaccine pCMV-hTRP-1 encoding TRP-1 |
| Vaccine Information |
- Vaccine Name: B16 melanoma DNA vaccine pCMV-hTRP-1 encoding TRP-1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0004430
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- TYRP1
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- Tyrp1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0005010
- Preparation: Vaccine is made with naked DNA encoding an alphavirus replicon (self-replicating mRNA) and the self/tumor antigen tyrosinase-related protein-1 with antigen expression controlled by cytomegalovirus (CMV) promoter (Leitner et al., 2003).
- Immunization Route: Gene gun
- Description: This vaccine has been used in research involving melanoma. (Leitner et al., 2003)
|
| Host Response |
|
Mouse Response
- Vaccine Immune Response Type: VO_0000286
- Efficacy: To test the efficacy of replicase-based TRP-1 plasmids, gene-gun−immunized mice were challenged subcutaneously with B16 melanoma. This vaccine provided strong tumor protection, with around 50% of mice still tumor-free 21 days after challenge (Leitner et al., 2003).
|
| References |
Leitner et al., 2003: Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nature medicine. 2003; 9(1); 33-39. [PubMed: 12496961].
|
|
